Brokerages expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings per share (EPS) of ($0.55) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Acorda Therapeutics’ earnings, with estimates ranging from ($0.86) to ($0.34). Acorda Therapeutics posted earnings per share of $0.45 during the same quarter last year, which suggests a negative year over year growth rate of 222.2%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 13th.

On average, analysts expect that Acorda Therapeutics will report full year earnings of ($2.13) per share for the current year, with EPS estimates ranging from ($2.43) to ($1.91). For the next year, analysts forecast that the company will report earnings of ($1.59) per share, with EPS estimates ranging from ($3.01) to $0.01. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.05. Acorda Therapeutics had a negative return on equity of 12.96% and a negative net margin of 155.89%. The company had revenue of $47.72 million during the quarter, compared to analysts’ expectations of $43.23 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The business’s quarterly revenue was down 66.6% compared to the same quarter last year.

A number of brokerages have weighed in on ACOR. JPMorgan Chase & Co. cut Acorda Therapeutics from a “neutral” rating to an “underweight” rating and set a $1.40 price target for the company. in a research report on Thursday, October 24th. HC Wainwright reiterated a “hold” rating and issued a $6.00 price objective on shares of Acorda Therapeutics in a research note on Monday, December 30th. Finally, ValuEngine upgraded Acorda Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $6.94.

Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new position in shares of Acorda Therapeutics in the third quarter worth about $33,000. Commonwealth Equity Services LLC bought a new position in shares of Acorda Therapeutics in the third quarter worth about $36,000. Comerica Bank increased its stake in shares of Acorda Therapeutics by 22.5% in the third quarter. Comerica Bank now owns 44,988 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 8,268 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Acorda Therapeutics by 171.7% in the third quarter. State of Alaska Department of Revenue now owns 36,931 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 23,336 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Acorda Therapeutics in the third quarter worth about $117,000.

Shares of NASDAQ:ACOR traded down $0.09 on Thursday, reaching $2.33. The company had a trading volume of 101,696 shares, compared to its average volume of 3,518,860. Acorda Therapeutics has a twelve month low of $1.49 and a twelve month high of $17.41. The stock has a 50-day moving average price of $1.98 and a 200 day moving average price of $3.33. The stock has a market capitalization of $113.35 million, a P/E ratio of 1.27 and a beta of 1.26. The company has a quick ratio of 3.12, a current ratio of 3.42 and a debt-to-equity ratio of 1.33.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Read More: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.